A string of high-profile entertainers have publicly attributed significant weight loss to GLP‑1 medications such as Ozempic, Mounjaro and Zepbound, sparking renewed attention to the drugs’ use outside clinical settings and debate over their effects.
Performers and television personalities have described losses ranging from a few stone to single-digit stone figures after starting prescriptions or, in some cases, switching between different brands. Some have been candid about side effects; others have emphasised lifestyle changes alongside medication.
Tennis great Serena Williams told media she lost about 31 pounds after starting Zepbound, a brand tied to Mounjaro, saying she began treatment in January and now feels "light physically and mentally." The 23‑time Grand Slam champion has described improved joint pain and continues to maintain a rigorous exercise routine. Her husband, Alexis Ohanian, is an investor in a distributor of the brand she named.
Television presenter Sharon Osbourne has said she dropped roughly four stone after beginning Ozempic in 2022, though she also reported difficult initial side effects, including vomiting. Osbourne has warned that the drug affected her metabolism and has acknowledged appearing gaunt, saying she "took it too far." British reality star Gemma Collins has reported steadier losses after starting Mounjaro this year, moving from a size 26 to a size 20 and saying she is aiming for further reduction.
Several musicians and actors have also discussed their experiences. Meghan Trainor told followers she lost about four stone after going on Mounjaro, citing friends and some medical professionals as influences on her decision. Robbie Williams said his appetite suppression after using a GLP‑1 treatment contributed to rapid weight loss that coincided with a diagnosis of scurvy, which he linked to insufficient vitamin C intake during a period of restricted eating. Singer Boy George wrote in his 2024 autobiography that he used Ozempic and later Mounjaro to maintain weight loss and avoid regain; he also underwent surgery to remove loose skin.
Oprah Winfrey confirmed in late 2023 that she had used a GLP‑1 medication and has described the prescription as an approved way to manage weight. Winfrey, who has publicly documented decades of weight fluctuation, has said the treatment helped her reach a personal target and that she adjusted daily habits, including avoiding food after midafternoon and increasing hiking.
Not all public figures have been unequivocal about medical treatment. Actress Rebel Wilson credited a change in diet, increased protein and calorie control for a major weight reduction that began in 2020; she later acknowledged a brief period of Ozempic use after losing weight. Wilson has also reported some regain since her initial losses.
Tesla and X owner Elon Musk has posted about using Wegovy in 2022 and later Mounjaro, describing gastrointestinal side effects and calling attention to the drugs on social media. Public disclosure and casual references by celebrities have coincided with growing consumer interest and supply pressures for prescriptions.
Medical practitioners have warned that while GLP‑1 receptor agonists can be effective for weight loss in people with obesity or certain medical needs, they can also cause side effects such as nausea, vomiting and nutritional deficiencies when diet is severely restricted. Dermatologic or aesthetic changes sometimes described as "Ozempic face" — increased facial gauntness associated with rapid loss of subcutaneous fat — have been reported anecdotally by patients and discussed in media coverage.
The public debate has widened to include questions about access and appropriateness. Advocates note the drugs are approved for treating obesity and related conditions when prescribed by physicians; critics and some clinicians caution about unsupervised use, potential long‑term effects, and the need for nutritional monitoring. Several celebrities who have publicly discussed their treatments have also emphasised combined approaches of medication, diet and exercise, while others have reported unintended health consequences.
As attention to GLP‑1 medications continues, clinicians and public health officials urge patients to consult healthcare providers for personalised assessment, monitoring and guidance rather than relying solely on anecdotal reports. The ongoing visibility of celebrity experiences has added momentum to conversations about weight‑management therapies, regulatory oversight and the balance between medical benefit and risk in the public eye.